Asthma - Pipeline Insight, 2024

Asthma - Pipeline Insight, 2024

DelveInsight’s, “Asthma - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Asthma: Understanding

Asthma: Overview

Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the airways. Symptoms of asthma include shortness of breath, cough, and wheezing. It commonly presents in childhood and is usually associated with conditions such as eczema and hay fever. Asthma comprises a range of diseases and has a variety of heterogeneous phenotypes. The recognized factors that are associated with asthma are a genetic predisposition, specifically a personal or family history of atopy (propensity to allergy, usually seen as eczema, hay fever, and asthma).

Asthma is a common pathology, affecting around 15% to 20% of people in developed countries and around 2% to 4% in less developed countries. It is significantly more common in children. Up to 40% of children will have a wheeze at some point, which, if reversible by beta-2 agonists, is termed asthma, regardless of lung function tests. Asthma is associated with exposure to tobacco smoke and inhaled particulates and is thus more common in groups with these environmental exposures.

Asthma is a condition of acute, fully reversible airway inflammation, often following exposure to an environmental trigger. The pathological process begins with the inhalation of an irritant (e.g., cold air) or an allergen (e.g., pollen), which then, due to bronchial hypersensitivity, leads to airway inflammation and an increase in mucus production. This leads to a significant increase in airway resistance, which is most pronounced on expiration. Patients will usually give a history of a wheeze or a cough, exacerbated by allergies, exercise, and cold. There is often diurnal variation, with symptoms being worse at night. Patients may give a history of other forms of atopy, such as eczema and hay fever. There may be some mild chest pain associated with acute exacerbations. Many asthmatics have nocturnal coughing spells but appear normal in the day time.

Pulse oximetry can be useful in assessing the severity of an asthma attack or monitoring for deterioration. Note that pulse oximetry lag, and the physiological reserve of many patients means that a falling pO2 on pulse oximetry is a late finding, indicating a severely unwell or peri-arrest patient. Peak flow measures also can be used to assess asthma and should always be checked against a nomogram as well as the individual patient's normal baseline function. The different severities of acute asthma attacks have an associated peak flow measurement, recorded as a certain percentage of expected peak flow. A chest x-ray is an important test, especially if patients have a history of risk of the potential foreign body or possible infection. A Chest CT scan is done in patients with recurrent symptoms who do not respond to therapy. Medical management includes bronchodilators like beta-2 agonists and muscarinic antagonists (salbutamol and ipratropium bromide respectively) and anti-inflammatories such as inhaled steroids (usually beclometasone but steroids via any route will be helpful).

""Asthma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.

Asthma Emerging Drugs Chapters

This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Asthma Emerging Drugs

GSK3511294: GlaxoSmithKline

GSK’294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. In patients with severe eosinophilic asthma, targeted anti-IL-5 therapies are a well-established and effective treatment approach. GSK3511294 is currently being investigated in Phase III stage of Clinical trial evaluation for the treatment of Asthma.

TQC2731: Chia Tai Tianqing Pharmaceutical Group

TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

AZD4604: AstraZeneca

AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care. Due to the broad anti-inflammatory properties of JAK1 inhibition, AZD4604 is predicted to provide benefit to steroid sensitive and insensitive asthma endotypes, thereby offering a differentiation opportunity from existing biologics. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

FB704A: Oneness Biotech Co., Ltd.

FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. FB704A (anti-IL-6 Ab) can reduce bronchial hyperresponsiveness as well as the Th1, Th2, and Th17 inflammatory responses of the respiratory tract, inhibit IL-6 classic- and trans-signaling pathways, and therefore have a chance of improving the symptoms of severe asthma (with high neutrophils) and severe mixed-granulocytic asthma. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.

ARO-RAGE: Arrowhead Pharmaceuticals

ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases. It is currently being investigated in Phase I stage of Clinical trial evaluation for the treatment of Asthma.

Further product details are provided in the report……..

Asthma: Therapeutic Assessment

This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Asthma

There are approx. 80+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.

Phases

DelveInsight’s report covers around 90+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Asthma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.

Asthma Report Insights

Asthma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Asthma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Asthma drugs?

How many Asthma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Asthma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GlaxoSmithKline

Chia Tai Tianqing Pharmaceutical Group

AstraZeneca

Oneness Biotech Co., Ltd.

Arrowhead Pharmaceuticals

Areteia Therapeutics

Jiangsu HengRui Medicine

SinoMab BioScience Ltd

Incyte Corporation

CSPC ZhongQi Pharmaceutical

Advagene Biopharma Co. Ltd.

Beijing Kanova Biopharmaceutical

Inmunotek

Roche

Sanofi

ARS Pharmaceuticals

Key Products

GSK3511294

TQC2731

Atuliflapon

AZD4604

FB704A

ARO-RAGE

Dexpramipexole

SHR-1703

SM17

ARO-MUC5AC

Povorcitinib

CM326

AD17002

XKH001

MM09

RG6341

Amlitelimab

Please Note: It will take 3-5 business days to complete the report upon order confirmation.